Studies reporting increased FAM57A expression in lung, liver, and head and neck cancers, when compared to the respective normal tissues [10,11,12,13,14], raise the possibility that there may exist a therapeutic window to preferentially target tumor cells. Here, TLCD3A is linked to head and neck cancer.